RegulatoryCompany release

FDA grants Breakthrough Therapy status to Armata's phage cocktail AP-SA02 for S. aureus bacteremia

🇺🇸 Armata Pharmaceuticals, Inc. (ARMP) · Thu 12 Nov 2026

Armata Pharmaceuticals also reported Q3 2026 net income of $54.9 million, driven by a loan fair-value gain, while it finalises its Phase 3 protocol with the FDA.

Armata Pharmaceuticals announced on 12 November 2026 that the US Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02. The product is a bacteriophage cocktail for adjunct treatment of complicated Staphylococcus aureus bacteremia.

The company said the agency has also agreed an initial pediatric study plan for the candidate. Armata is still finalising the Phase 3 protocol with the FDA, and the source gives no timetable for the start of that trial.

In its third-quarter 2026 results, Armata reported net income of $54.9 million. The company attributed this to a fair-value gain on a convertible loan rather than to operating performance. Unrestricted cash stood at $18.3 million.

Armata also received a further $3.7 million from the US Department of War. The summary provided does not say what the funding covers or how it fits into earlier awards.

For context, Breakthrough Therapy designation is an FDA programme intended to speed the development and review of drugs for serious conditions where early clinical evidence suggests a substantial improvement over available therapy. It does not guarantee approval.

What it means for your team

  • The designation signals closer FDA engagement on AP-SA02, which may help shape the Phase 3 design and the wider development pathway for phage-based therapies.
  • The agreed initial pediatric study plan indicates that paediatric requirements are being addressed alongside the adult programme.
  • Teams tracking phage therapy should watch for the final Phase 3 protocol, as it could set expectations for endpoints and evidence in this emerging product class.
  • The Q3 profit stems from a non-operating fair-value gain, and cash of $18.3 million is modest, so funding for late-stage development remains a point to monitor.

Company's press release (SEC filing): Armata Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Armata Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →